These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1009699)

  • 1. Whole-blood thrombin time: a bedside method for determination of heparin activity.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1976 Dec; 6(6):523-5. PubMed ID: 1009699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Measurement of activated whole blood coagulation as a control parameter for heparin dosage in hemodialysis].
    Kraatz G; Lopot F
    Z Urol Nephrol; 1984 Aug; 77(8):465-71. PubMed ID: 6495895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
    Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J
    Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
    Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
    Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1983 Feb; 19(2):82-6. PubMed ID: 6839556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Control of the heparin induced bleeding risk in haemodialysis patients (author's transl)].
    Vogel GE; Kopp KF
    Med Klin; 1976 Jan; 71(3):116-9. PubMed ID: 1250190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heparin and antiheparin in young children. 1. Report: development of a method for determining heparin and antiheparin in the antithrombin-thrombin system].
    Domula M; Weissbach G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(5):808-23. PubMed ID: 6188669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of heparin in blood plasma].
    Kotovshchikova MA; Krasko SS
    Lab Delo; 1974; 8(0):460-3. PubMed ID: 4139363
    [No Abstract]   [Full Text] [Related]  

  • 10. [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].
    Lutze G; Presser HJ; Urbahn H
    Z Gesamte Inn Med; 1989 Apr; 44(8):235-40. PubMed ID: 2662657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

  • 14. [Activated thromboplastin time, plasma heparin and plasma fibrinogen using the Fibrintimer 10].
    Khayat MC; Laforet F; Khayat A; Derlon A; Lequerrec A; Thomas M
    Ann Biol Clin (Paris); 1988; 46(8):696-700. PubMed ID: 3218791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of blood heparin levels--variation in results with assay method.
    Juhan-Vague I; Riera H; Aillaud MF; Verdet D; Sambuc R
    Thromb Haemost; 1982 Jun; 47(3):295. PubMed ID: 7112503
    [No Abstract]   [Full Text] [Related]  

  • 16. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma heparin estimation based upon a thrombin clotting time technique.
    Phillips JD
    Med Lab Sci; 1979 Apr; 36(2):141-5. PubMed ID: 470560
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1988 Dec; 60(3):377-81. PubMed ID: 2853458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
    Haskel EJ; Eisenberg PR; Abendschein DR
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relation of the formation of the fibrin network of a blood clot to the amount of thrombin in complexes with endogenous heparin].
    Ishmukhametova DN; Mozhina AA
    Anesteziol Reanimatol; 1984; (2):30-4. PubMed ID: 6742497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.